l-Carnitine supplementation improves the behavioral symptoms in autistic children.

Abstract: l-Carnitine was proposed as a potential treatment for patients diagnosed with autism to ameliorate the behavioral symptoms associated with the disease. Thirty children diagnosed with autism were randomly assigned to receive (100mg/kg bodyweight/day) of liquid l-carnitine (n =16) or placebo (n =14) for 6 months. Measurements included changes in childhood autism rating scale (CARS) form and free and total carnitine levels using tandem mass spectrometry. Results showed significant improvement in CARS scores (P-groups <0.001) and (P-overtime=0.006), with statistically significant differences in free carnitine levels (P =0.027) and total carnitine levels (P =0.036). There was no correlation between baseline free and total carnitine levels with changes in CARS scores from zero to 6 months (r >0.5, P >0.05) and generally l-carnitine therapy was well tolerated. In conclusion, l-carnitine therapy (100mg/kg bodyweight/day) administered for 6 months significantly improved the autism severity, but subsequent studies are recommended. [Copyright &y& Elsevier]

Copyright of Research in Autism Spectrum Disorders is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)